高级检索
当前位置: 首页 > 详情页

Antiplatelet activity of loureirin A by attenuating Akt phosphorylation: In vitro studies.

文献详情

资源类型:
Pubmed体系:
机构: [1]Department of Pharmacology,School of Basic Medicine,Tongji Medical College of Huazhong University of Scienceand Technology,Wuhan 430030,China [2]The Key Laboratory for DrugTarget Researchesand Pharmacodynamic Evaluation of Hubei Province,Wuhan 430030,China [3]Department of Pharmacy,The First Affiliated Hospital of Shantou University Medical College,Shantou,Guangdong 515041,China [4]Department of Traditional Chinese Medicine,Renmin Hospital of Wuhan University,Wuhan 430060,China
出处:
ISSN:

关键词: Loureirin A Platelet Aggregation Spreading PI3K/Akt

摘要:
Loureirin A is a flavonoid extracted from Dragon׳s Blood that has been used to promote blood circulation and remove stasis in Chinese traditional medicine. However, the mechanisms of these effects are not fully understood. We explored the anti-platelet activity and underlying mechanism of loureirin A in vitro. Our results indicated that loureirin A negatively affected agonist-induced platelet aggregation such as collagen, collagen-related peptide (CRP), ADP and thrombin. Loureirin A inhibited collagen-induced platelet ATP secretion and thrombin-stimulated P-selectin expression in a dose-dependent manner. Platelet spreading on immobilized fibrinogen was significantly impaired in the presence of loureirin A. Immunoblotting analysis indicated that 100μM of loureirin A almost completely eliminated collagen-induced Akt phosphorylation at Ser473. Interestingly, a submaximal dose (50μM) of loureirin A had an additive inhibitory effect with the phosphoinositide 3-kinase (PI3K) inhibitor Ly294002 on collage-induced Akt phosphorylation in platelets. Taken together, loureirin A had an inhibitory effect on platelet activation, perhaps through an impairment of PI3K/Akt signaling. Copyright © 2014 Elsevier B.V. All rights reserved.

基金:
语种:
PubmedID:
中科院(CAS)分区:
出版当年[2014]版:
大类 | 3 区 医学
小类 | 3 区 药学
最新[2025]版:
大类 | 3 区 医学
小类 | 2 区 药学
第一作者:
第一作者机构: [1]Department of Pharmacology,School of Basic Medicine,Tongji Medical College of Huazhong University of Scienceand Technology,Wuhan 430030,China [2]The Key Laboratory for DrugTarget Researchesand Pharmacodynamic Evaluation of Hubei Province,Wuhan 430030,China [3]Department of Pharmacy,The First Affiliated Hospital of Shantou University Medical College,Shantou,Guangdong 515041,China
共同第一作者:
通讯作者:
通讯机构: [1]Department of Pharmacology,School of Basic Medicine,Tongji Medical College of Huazhong University of Scienceand Technology,Wuhan 430030,China [2]The Key Laboratory for DrugTarget Researchesand Pharmacodynamic Evaluation of Hubei Province,Wuhan 430030,China [*1]Department of Pharmacology, School of Basic Med- icine, Tongji Medical College of Huazhong University of Science and Technology, No.13 Hangkong Road, Wuhan 430030 China.
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:2018 今日访问量:0 总访问量:645 更新日期:2024-07-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 广东省中医院 技术支持:重庆聚合科技有限公司 地址:广州市越秀区大德路111号